pyridoxine has been researched along with Metastase in 9 studies
4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol: structure in first source
vitamin B6 : Any member of the group of pyridines that exhibit biological activity against vitamin B6 deficiency. Vitamin B6 deficiency is associated with microcytic anemia, electroencephalographic abnormalities, dermatitis with cheilosis (scaling on the lips and cracks at the corners of the mouth) and glossitis (swollen tongue), depression and confusion, and weakened immune function. Vitamin B6 consists of the vitamers pyridoxine, pyridoxal, and pyridoxamine and their respective 5'-phosphate esters (and includes their corresponding ionized and salt forms).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pyridoxine, an activated form of vitamin B6 used to treat allergic dermatitis, may prevent capecitabine-associated hand-foot syndrome (HFS), although evidence of the benefit of prophylactic pyridoxine is lacking." | 9.27 | A randomized phase II study evaluating pyridoxine for the prevention of hand-foot syndrome associated with capecitabine therapy for advanced or metastatic breast cancer. ( Hattori, M; Hayashi, T; Iwata, H; Kobayashi, N; Nakada, T; Saito, K; Sawaki, M; Toyama, T; Tsuneizumi, M; Yokota, I; Yoshimura, A, 2018) |
| "Prophylactic pyridoxine was given to 38 patients receiving capecitabine (alone or in combination with cyclophosphamide) for metastatic breast cancer and compared with historical data from 40 patients receiving capecitabine without pyridoxine in our clinic." | 7.76 | Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer. ( Fujita, T; Hayashi, H; Iwata, H; Kimura, M; Kondo, N; Toyama, T; Tsunoda, N; Tsuzuki, N; Yamashita, H; Yamashita, T; Yoshimoto, N, 2010) |
| "Pyridoxine, an activated form of vitamin B6 used to treat allergic dermatitis, may prevent capecitabine-associated hand-foot syndrome (HFS), although evidence of the benefit of prophylactic pyridoxine is lacking." | 5.27 | A randomized phase II study evaluating pyridoxine for the prevention of hand-foot syndrome associated with capecitabine therapy for advanced or metastatic breast cancer. ( Hattori, M; Hayashi, T; Iwata, H; Kobayashi, N; Nakada, T; Saito, K; Sawaki, M; Toyama, T; Tsuneizumi, M; Yokota, I; Yoshimura, A, 2018) |
| "Prophylactic pyridoxine was given to 38 patients receiving capecitabine (alone or in combination with cyclophosphamide) for metastatic breast cancer and compared with historical data from 40 patients receiving capecitabine without pyridoxine in our clinic." | 3.76 | Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer. ( Fujita, T; Hayashi, H; Iwata, H; Kimura, M; Kondo, N; Toyama, T; Tsunoda, N; Tsuzuki, N; Yamashita, H; Yamashita, T; Yoshimoto, N, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (77.78) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Toyama, T | 2 |
| Yoshimura, A | 1 |
| Hayashi, T | 1 |
| Kobayashi, N | 1 |
| Saito, K | 1 |
| Tsuneizumi, M | 1 |
| Sawaki, M | 1 |
| Hattori, M | 1 |
| Nakada, T | 1 |
| Yokota, I | 1 |
| Iwata, H | 2 |
| Yoshimoto, N | 1 |
| Yamashita, T | 1 |
| Fujita, T | 1 |
| Hayashi, H | 1 |
| Tsunoda, N | 1 |
| Kimura, M | 1 |
| Tsuzuki, N | 1 |
| Yamashita, H | 1 |
| Kondo, N | 1 |
| Gatzemeier, U | 1 |
| Jüngst, G | 1 |
| Wagner, G | 1 |
| Lewis, RA | 1 |
| Clark, RB | 1 |
| Gridley, DS | 1 |
| Stickney, DR | 1 |
| Nutter, RL | 1 |
| Slater, JM | 1 |
| Shultz, TD | 1 |
| von Ardenne, M | 1 |
| Chaplain, RA | 1 |
| Yoshida, O | 1 |
| Brown, RR | 1 |
| Bryan, GT | 1 |
| Mönch, E | 1 |
| Stefan, H | 1 |
| Käser, H | 1 |
| Lee, GR | 1 |
| Cartwright, GE | 1 |
| Wintrobe, MM | 1 |
1 trial available for pyridoxine and Metastase
| Article | Year |
|---|---|
A randomized phase II study evaluating pyridoxine for the prevention of hand-foot syndrome associated with capecitabine therapy for advanced or metastatic breast cancer.
Topics: Aged; Breast Neoplasms; Capecitabine; Female; Hand-Foot Syndrome; Humans; Middle Aged; Neoplasm Meta | 2018 |
8 other studies available for pyridoxine and Metastase
| Article | Year |
|---|---|
Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deo | 2010 |
[Chemotherapy of inoperable endothoracic tumours (results of the Karrer and aco polycytostatic therapy) (author's transl)].
Topics: Adult; Aged; Bronchial Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; | 1979 |
Infiltrative retinopathy in systemic lymphoma.
Topics: Cobalt; Cyclophosphamide; Eye Neoplasms; Female; Fluorescein Angiography; Fundus Oculi; Humans; Ison | 1975 |
Suppression of tumor growth and enhancement of immune status with high levels of dietary vitamin B6 in BALB/c mice.
Topics: Animals; Body Weight; Eating; Liver; Lymphocyte Activation; Male; Mice; Mice, Inbred BALB C; Mitogen | 1987 |
The inhibitory effect of B-group vitamins on the incidence of tumour metastases.
Topics: Animals; Lung Neoplasms; Mammary Neoplasms, Experimental; Mice; Neoplasm Metastasis; Niacinamide; Ox | 1971 |
A possible role of urinary metabolites of tryptophan in the heterotopic recurrence of bladder cancer in man.
Topics: Carcinogens; Humans; Neoplasm Metastasis; Nutritional Physiological Phenomena; Pyridoxine; Tryptopha | 1971 |
[Pepper type neuroblastoma with homocystinuria. Diagnosis, biochemistry and therapy].
Topics: Amino Acids; Catecholamines; Child, Preschool; Cyclophosphamide; Dopamine; Homocystinuria; Humans; L | 1970 |
The response of free erythrocyte protoporphyrin to pyridoxine therapy in a patient with sideroachrestic (sideroblastic) anemia.
Topics: Aged; Anemia; Blood Sedimentation; Deferoxamine; Erythrocytes; Hemoglobins; Humans; In Vitro Techniq | 1966 |